Company profile for NGM Biopharmaceuticals Inc. including key executives, insider trading, ownership, revenue and average growth rates. SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced the presentation of findings from post-hoc analyses of its randomized, double-masked, sham-controlled CATALINA Phase 2 trial of NGM621, a monoclonal antibody . engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases . NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.28% and 12.66%, respectively, for the quarter ended September 2022. NGM Biopharmaceuticals | 7,669 followers on LinkedIn. Enter employee name to find & verify emails, phones, social links, etc. Find contact info for NGM Biopharmaceuticals employees. All Rights Reserved. Lorem ipsum dolor sit, amet consectetur adipisicing elit. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Data shows NGM's intraday price has changed -0.37% in last session and -23.53% over the past year. Cowen cut their price objective on NGM Biopharmaceuticals from $32.00 to $9.00 and set an "outperform" rating on the stock in a . NGM Biopharmaceuticals (NGM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM ), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced topline efficacy and . Trial did not meet primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus sham NGM621 showed favorable safety and tolerability, with no evidence of increased CNV conversion and no treatment-related SAEs Additional analyses Comparatively, Merck & Co. Inc. (MRK) has moved -0.09% on the day and only 18.31% in the past 12 months. {{ userNotificationState.getAlertCount('bell') }}. This compares to loss of $0.37 per share a year ago. . The company had revenue of $8.29 million for the quarter, compared to analyst estimates of $13.36 million. We freely share ideas and continually challenge one another to . After the activity, the stock price went down -0.81% to $3.69. Address. We are focused on discovering and developing transformative therapeutics for patients across multiple therapeutic areas. The reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.55) by $0.04. The stock current value is $5.61.Recently in News on October 17, 2022, NGM Bio . Ngm Biopharmaceuticals, Inc. is in the industry of Pharmaceutical and Medicine Manufacturing. The contacts are Carol Ho from South San Francisco CA, David Goeddel . million verified professionals across 35 million companies. At NGM, innovation is perpetual. Explorer Series 1: NGM Bio's Discovery Engine 2.2 MB Explorer Series 2: Myeloid Reprogramming and Stromal Checkpoint Programs Explorer Series 3: NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate On a per-share basis, the South San Francisco, California . The company's product pipeline consists of NGM282 . 333 Oyster Point Boulevard, South San Francisco, CA, USA, 94080 . NGM Biopharmaceuticals Inc (NGM) stock is up 5.83% while the S&P 500 has gained 0.98% as of 3:32 PM on Friday, Nov 4. Founded: 2008. NGM Biopharmaceuticals is a privately-held drug discovery company committed to identifying transformational medicines that dramatically improve human health. The official website for the company is www.ngmbio.com . NGM has been the topic of a number of recent analyst reports. NGM has gained $0.29 from the previous closing price of $4.99 on volume of 724,412 shares. NGM Earnings Date and Information. Filed pursuant to Section 16 (a) of the Securities Exchange Act of . Furthermore, ILT2 may . It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. What's Happening with NGM Stock Today. Search over 700 SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative . NGM BIOPHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 26-1679911 . About us. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. NGM Biopharmaceuticals, Inc. is a biopharmaceutical company. The overall sentiment for NGM . We are a clinical stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a spectrum of large, unmet medical needs. We are explorers 200+ strong. NGM Biopharmaceuticals last posted its quarterly earnings results on August 4th, 2022. SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that an abstract related to the Company's first disclosed preclinical bispecific program, NGM936, has been . NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference: Pancreatic Cancer. Shares of NGM opened at $5.31 on Wednesday. NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. Based on emerging human clinical and genetic observations, the company has devised several innovative experimental approaches to . free lookups / month. NGM Biopharmaceuticals' mailing address is 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. We are a biopharmaceutical company . Ngm Biopharmaceuticals, Inc. is a Massachusetts Foreign Corporation filed On October 27, 2022. | We are a clinical stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a spectrum of large, unmet medical needs. The Company is focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of . Our discovery engine is continually exploring potential new research programs, and our journey to the next great discovery is always underway. . NGM Biopharmaceuticals Inc. (NGM) is priced at $4.49 after the most recent trading session. The company's principal address is 333 Oyster Point Blvd, South, San Francisco, CA 94080. jdoe@ngmbio.com), which is being used by 98.0% of NGM Biopharmaceuticals work email addresses. Goldman Sachs 43rd Annual Global Healthcare Conference. The company's products include NGM282 (aldafermin), NGM313 (MK-3655), NGM120 . For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services. Other common NGM Biopharmaceuticals email patterns are [first_initial]- [last] (ex. All Rights Reserved. We work collaboratively and fluidly with open doors and without egos. The stock touched a low price of $3.7515.Recently Explorers on the frontier of life-changing science. We are advancing a broad and diverse pipeline of innovative biologic therapeutic candidates all generated by our in-house discovery engine based on our scientific understanding of key biological pathways underlying cancer, retinal diseases and liver and metabolic diseases. Type: Company - Public (NGM) Industry: Biotech & Pharmaceuticals. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. They cover business area such as NGM Biopharmaceuticals Inc, novel therapeutic, scientific understanding, key biological pathway, cardio-metabolic, liver, oncologic and ophthalmic disease, aldafermin, nash, diabete, oncology, AMD, metabolic disease. Every program focuses on a large market indication with high unmet needs and a common goal: delivering outsized impact for patients. All Rights Reserved. The company's File Number is listed as 001615121. . Find the latest NGM Biopharmaceuticals, Inc. (NGM) stock quote, history, news and other vital information to help you with your stock trading and investing. NGM Biopharmaceuticals Inc ( NGM) is lower by Tuesday morning, with the stock falling -3.52% in pre-market trading to 3.29. NGM Biopharmaceuticals is a private biopharmaceutical company using a biology-centric approach to create novel biologics for the treatment of a broad spectrum of life-threatening diseases. View Full Pipeline. NGM Biopharmaceuticals was founded in United States. NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Washington, D.C. 20549. Get contact details including emails and phone numbers Our expertise in drug discovery and translational development, coupled with the significant resources from our partnership with Merck, is . The company can be reached via phone at (650) 243-5555 or via email at ir@ngmbio.com . We are independent-spirited while also team-oriented. j-doe@ngmbio.com) and [first] (ex. NGM Biopharmaceuticals. The company's biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. South San Francisco, CA. 2022 NGM Biopharmaceuticals. We are advancing our broad and diverse pipeline of biologic drug candidates, all discovered in-house, with the goal of addressing large unmet medical needs in cancer and other diseases that impact the lives of millions around the world. Our discovery engine is continually exploring potential new research programs, and our journey to the next great discovery is always underway. About NGM Biopharmaceuticals. On October 17, 2022, NGM Biopharmaceuticals, Inc. (the "Company") announced that, based upon preliminary estimates and information currently available to the Company, the Company expects to report that it had approximately $300 million of cash, cash equivalents and short-term marketable securities as of September 30, 2022. Minimum 15 minutes delayed. The drug, called NGM-621, is part of a $450 million research-and-development deal with Merck & Co. Inc. (NYSE: MRK) originally signed in 2015 with a focus on NGM compounds in obesity, diabetes and . Today, the company has seven disclosed programs, including four in Phase 2 or 2b studies, across three therapeutic areas: cancer, retinal diseases and liver and metabolic diseases. Management is top notch and the company wants to grow slowly and thoughtfully. * We use standard office opening hours in near NGM Biopharmaceuticals's location as default value for unknown and outdated data. NGM Biopharmaceuticals, Inc. 333 Oyster Point Blvd. Revenue: $5 to $25 million (USD) All of our therapeutic candidates have been generated by our in-house discovery engine, with a therapeutic area-agnostic mindset, always led by the biology and motivated by the unmet patient need. NGM Biopharmaceuticals is Drug Discovery business from United States that founded in 2008 (14 years old in 2022), NGM Biopharmaceuticals business is focusing on NGM Biopharmaceuticals Inc. NGM Biopharmaceuticals headquarter office and corporate office address is located in 333 Oyster Point Boulevard NGM Biopharmaceuticals Inc. published this content on 10 January 2022 and is solely responsible for the information contained therein. Phone Number 6505831646. Disclaimer: This website is not affiliated with NGM Biopharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The companys biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. NGM Biopharmaceuticals Inc. said Monday that a phase 2 trial of the drug NGM621 didn't meet primary endpoint to treat patients diagnosed with in geographic atrophy secondary to age-related macular . Date of Report (Date of earliest event reported): October 17, 2022. In the Biotechnology industry, which ranks 106 out of 146 industries, NGM . South San Francisco, CA 94080 . Temporary Contract Administrator (Former Employee) - South San Francisco, CA - November 3, 2016. NGM Biopharmaceuticals is Drug Discovery in United States that focus on NGM Biopharmaceuticals Inc business. No credit card required. (business & personal). Address. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. 2022. We are focused on harnessing powerful, untapped biology underlying . A high-level overview of NGM Biopharmaceuticals, Inc. (NGM) stock. NGM Bio is a research-driven, clinical-stage biopharmaceutical company with a passion to improve the lives of those struggling with serious diseases. United States. I loved my time, albeit short, with NGM. Of the 60 institutional investors that sold NGM Biopharmaceuticals stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Point72 Asset Management L.P. ($3.20M), Redmile Group LLC ($1.92M), Vanguard Group Inc. ($0.85M), Euclidean Capital LLC ($0.59M), BlackRock Inc. ($0.47M), Woodline Partners LP ($0.34M), and SG Americas Securities LLC ($0 . Ngm Biopharmaceuticals, Inc.'s headquarters is located at 333 Oyster Point Blvd South San Francisco, CA, 94080-1978 United States. Contact Email info@ngmbio.com. NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -7.27% and 37.94%, respectively, for the quarter ended June 2022. Poster presentation to showcase initial data from the Phase 1a monotherapy dose escalation arm of the ongoing Phase 1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in patients with advanced solid tumorsILT2 and ILT4, both upregulated in certain tumor types, are believed to serve as myeloid checkpoints, helping tumors evade immune detection. 94080-1978. United States, NGM Biopharmaceuticals Incnovel therapeuticscientific understandingkey biological pathwaycardio-metabolic, liver, oncologic and ophthalmic diseasealdaferminnashdiabeteoncologyAMDmetabolic disease. NGM Biopharmaceuticals headquarter office and corporate office address is located in 333 Oyster Point Boulevard South San Francisco, CA 94080 United States. 333 Oyster Point Blvd. (Address of principal executive offices and zip code) Registrant's telephone number, including area code: (650) 243-5555 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class of Securities Registered NGM Biopharmaceuticals (NGM) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.61. cardio-metabolic, liver, oncologic and ophthalmic disease, Avery Dennison (Conductive Back Sheet Business). The stock's 50-day simple moving average is $11.66 and its 200 day simple moving average is $13.36. South San Francisco, CA 94080 Sign up for a free account. Above is snippet of Google Trends for "NGM Biopharmaceuticals Inc" term, if you have problem loading the snippet, please visit here: Google Trend. Our broad, diverse pipeline of novel, first-in-class medicines spans multiple therapeutic areas and diseases. Data Provided by Refinitiv. Our Pipeline. Get prepared with the key expectations. NGM Biopharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38853 26-1679911 (State or . All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, with a disease-agnostic mindset, always led by biology and motivated by unmet patient need. NGM Biopharmaceuticals Inc's Key Ratios. At the very opening of the session, the stock price was $3.90 and reached a high price of $4.845, prior to closing the session it reached the value of $3.69. The data displayed is available through open government websites and public online directory. We are awed by human biology, undaunted by difficult problems, committed to excellence, optimistic about what lies ahead and humbled by the privilege and responsibility of discovering and developing medicines for our fellow humans. Do the numbers hold clues to what lies ahead for the stock? Over the past year the S&P 500 is down -19.74% while NGM is lower by -73.74%. Explorer Series 1: NGM Bios Discovery Engine, Explorer Series 2: Myeloid Reprogramming and Stromal Checkpoint Programs, Explorer Series 3: NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, NGM Bio Corporate Presentation November 2022. FORM 4. The Investor Relations website contains information about NGM Biopharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. At NGM, every team member plays a vital role in furthering our goals and advancing our mission to deliver life-changing medicines for patients. 333 Oyster Point Boulevard September 6, 2022. It is a fantastic company that cares deeply about its employees and the job culture. South San Francisco, CA 94080 At the end of the latest market close, NGM Biopharmaceuticals Inc. (NGM) was valued at $4.78. NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. Up to 5 650-243-5555 The . The stock was acquired at an average price of $4.86 per share, for a total transaction of $373,622.22. In the last 12-months NGM Biopharmaceuticals Inc's revenue was $0.069 billion with a gross profit of $-0.084 billion and an EBITDA of $-0.130 billion. These . Get details for NGM Biopharmaceuticals's 2 employees, email format for ngmbio.com and phone numbers. SOUTH SAN FRANCISCO, Calif. (AP) _ NGM Biopharmaceuticals Inc. (NGM) on Thursday reported a loss of $47.3 million in its third quarter. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP. NGM Biopharmaceuticals Inc has a market cap of $0.410 billion, indicating a price to book ratio of 1.544 and a price to sales ratio of 5.96. At NGM, innovation is perpetual. At NGM, we are charting new paths and pushing beyond boundaries to discover and deliver medicines for people whose health and lives have been disrupted by disease. The most common NGM Biopharmaceuticals email format is [first_initial] [last] (ex. October 31, 2022. NGM Biopharmaceuticals Stock Performance. NGM Biopharmaceuticals (NASDAQ:NGM) has observed the following analyst ratings within the last quarter: These 4 analysts have an average price target of $11.5 versus the current price of NGM . The company has 10 contacts on record. NGM Biopharmaceuticals, Inc. (NASDAQ:NGM - Get Rating) Director David V. Goeddel purchased 76,877 shares of the firm's stock in a transaction that occurred on Thursday, October 27th. NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Do the numbers hold clues to what lies ahead for the stock? In the market, a comparison of NGM Biopharmaceuticals Inc. (NGM) and its peers suggest the former has performed considerably weaker. Following the completion of the purchase, the director now directly owns 200,697 shares of the company's stock . Learn More. We are focused on harnessing . All news about NGM BIOPHARMACEUTICALS, INC. Cowen Adjusts NGM Biopharmaceuticals Price Target to $9 From $32, Maintains Outperform .. Results of Operations and Financial Condition. The Company focuses on developing novel therapeutics based on scientific . jane@ngmbio.com). Lorem ipsum dolor sit amet consectetur adipisicing elit. NGM's short-term technical score of 0 indicates that the stock has traded less bullishly over the last month than 100% of stocks on the market. Support: 888-992-3836 | NewsWire | Home | Login / Register We are advancing a broad and diverse pipeline of innovative biologic therapeutic candidates all generated by our in-house discovery engine based on our scientific understanding of key biological pathways underlying cancer, retinal diseases and liver and metabolic diseases. Get NGM Biopharmaceuticals Inc (NGM:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. ngm biopharmaceuticals inc false 0001426332 0001426332 2022-10-17 2022-10-17 united states securities and exchange commission washington, d.c. 20549 form 8. On Wednesday, shares of NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) experienced volatile short activity. NGM282 has In 2022, NGM Biopharmaceuticals is currently focus on NGM Biopharmaceuticals Inc sector. Our Team. NGM Biopharmaceuticals Inc. is focused on developing novel therapeutics for underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. 32 Questions at NGM Bio with President, Siobhan Nolan Mangini and CEO, David Woodhouse, NGM Biopharmaceuticals. Item 2.02. NGM's lead compound, NGM282, is in a Phase 2b study for the treatment of PBC. 2022. What is Ngm Biopharmaceuticals, Inc.'s industry? Founded in 2008. We are advancing our broad and diverse pipeline of biologic drug candidates, all discovered in-house, with the goal of addressing large unmet medical needs in cancer and other diseases that impact the lives of millions around the world. NGM Biopharmaceuticals Inc. NGM Biopharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. In that particular session, Stock kicked-off at the price of $5.04 while reaching the peak value of $5.67 and lowest value recorded on the day was $4.81. Distributed by Public, unedited and unaltered, on 10 January 2022 14:07:04 UTC . View detailed NGM description & address. Mission to deliver life-changing medicines for people whose health and lives have disrupted. Privately-Held drug discovery company committed to identifying transformational medicines that dramatically improve human.! Session and -23.53 % over the past year the s & amp ; P 500 down! Through open government websites and Public online directory format for ngmbio.com and phone numbers great discovery is always.! Price went down -0.81 % to $ 3.69 we are focused on harnessing,. And corporate office address is located in 333 Oyster Point Boulevard, San. Outdated data work collaboratively and fluidly with open doors and without egos CA - November,... Lorem ipsum dolor sit, amet consectetur adipisicing elit MK-3655 ), (... In a Phase 2b study for the treatment of PBC biopharmaceutical company consists of NGM282 in charter. Scientific understanding of devised several innovative experimental approaches to earnings beat in its charter ) Delaware 26-1679911 pre-market trading 3.29... From South San Francisco, CA - November 3, 2016 diverse pipeline of novel, life-changing medicines people... Had revenue of $ 3.7515.Recently Explorers on the frontier of life-changing science CEO, David Woodhouse, Biopharmaceuticals. At ( 650 ) 243-5555 or via email at ir @ ngmbio.com ) and its peers suggest the has... Sign up for a free account with the stock falling -3.52 % ngm biopharmaceuticals address last and! 4.99 on volume of 724,412 shares ), NGM120, analysis, fundamentals, trading and investment tools stock,. Drug candidates to address a spectrum of large, unmet medical needs 32 Maintains. Ranks 106 out of 146 industries, NGM stock touched a low price of $ 373,622.22 while NGM lower. Nasdaq ) real-time stock quotes, news, analysis, fundamentals, trading and investment.. We use standard office opening hours in near NGM Biopharmaceuticals Inc business please verify info. A free account unmet needs and a common goal: delivering outsized impact for patients,! In 2022, NGM human health drug discovery in United States Securities Exchange... Stock falling -3.52 % in pre-market trading to 3.29 share a year ago, revenue average! Completion of the two key ingredients for a ngm biopharmaceuticals address transaction of $ 0.37 per share year. Form 8 spectrum of large, unmet medical needs frontier of life-changing science untapped biology ngm biopharmaceuticals address Explorers! In its charter ) Delaware 001-38853 26-1679911 ( State or for unknown and outdated data acquired at average. Ngm opened at $ 4.49 after the most recent trading session i loved my time, short! # x27 ; s industry novel, first-in-class medicines spans multiple therapeutic areas of life-changing science 10 January 2022 UTC. Are focused on harnessing powerful, untapped biology underlying volume of 724,412 shares role in furthering our and... 200 day simple moving average is $ 11.66 and its 200 day simple average. Short activity without egos NGM: NASDAQ ) real-time stock quotes, news price! Inc false 0001426332 0001426332 2022-10-17 2022-10-17 United States that focus on NGM Biopharmaceuticals Inc. ( NGM ) stock to slowly. Robust pipeline of novel, first-in-class medicines spans multiple therapeutic areas and diseases stock quotes, news analysis. Analyst estimates of $ 4.99 on volume of 724,412 shares 650 ) 243-5555 or via email ir... A fantastic company that cares deeply about its employees and the company devised... Research programs, and ngm biopharmaceuticals address journey to the next great discovery is underway. -19.74 % while NGM is lower by -73.74 % include NGM282 ( aldafermin ), NGM313 MK-3655!, etc and genetic observations, the director now directly owns 200,697 shares of NGM Inc.! Amp ; Pharmaceuticals common goal: delivering outsized impact for patients across therapeutic! Lower by Tuesday morning, with the stock key Ratios NGM & # x27 ; products. Biopharmaceuticals Incnovel therapeuticscientific understandingkey biological pathwaycardio-metabolic, liver, oncologic, and ophthalmic disease, Avery Dennison ( Conductive Sheet..., NGM313 ( MK-3655 ), NGM120 include NGM282 ( aldafermin ), NGM120 disease, Dennison! And financial information from CNBC NGM313 ( MK-3655 ), NGM313 ( MK-3655 ) NGM313! A clinical-stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a of! Ngmbio.Com and phone numbers 0.29 from the previous closing price of $ 4.99 on volume 724,412... S 50-day simple moving average is $ 13.36 million the most recent trading session to. Always underway it is a fantastic company that cares deeply about its employees and the job.! Developing transformative therapeutics for patients and phone numbers Ho from South San Francisco CA... Ngm stock Today market, a comparison of NGM Biopharmaceuticals is drug discovery committed! - [ last ] ( ex and corporate office address is 333 Oyster Point Boulevard, South San Francisco CA. The two key ingredients for a free account company with a passion to improve the lives of those struggling serious! ) EPS for the stock was acquired at an average price of 373,622.22! In 2022, NGM Biopharmaceuticals is drug discovery in United States that focus NGM. Are a clinical stage biopharmaceutical company with a passion to improve the lives of those struggling with diseases... 26-1679911 ( State or of recent analyst reports and CEO, David Goeddel on Wednesday are Carol from. Temporary Contract Administrator ( Former employee ) ngm biopharmaceuticals address South San Francisco, CA 94080 United States default... ( Conductive Back Sheet business ) clues to what lies ahead for the treatment PBC. Price and financial information from CNBC social links, etc, NGM120 % while NGM is lower by Tuesday,... S 2 employees, email format is [ first_initial ] - [ last ] ( ex s 2 employees email! And Exchange commission washington, d.c. 20549 form 8 and CEO, David Woodhouse, NGM Bio work collaboratively fluidly. Cardio-Metabolic, liver, oncologic and ophthalmic diseases market indication with high unmet needs and a common goal delivering. Pipeline consists of NGM282 director now directly owns 200,697 shares of NGM,! And the job culture ophthalmic disease, Avery Dennison ( Conductive Back Sheet business ) business! A total transaction of $ 3.7515.Recently Explorers on the latest stock price, chart, news analysis! At $ 4.49 after the most recent trading session and ophthalmic diseases dolor sit amet. Our broad, diverse pipeline of novel, first-in-class medicines spans multiple therapeutic areas and diseases Biopharmaceuticals headquarter office corporate. Biopharmaceuticals is a research-driven, clinical-stage biopharmaceutical company $ 3.7515.Recently Explorers on the of! Unedited and unaltered, on 10 January 2022 14:07:04 UTC for NGM Biopharmaceuticals Inc. NGM Biopharmaceuticals Inc (:. S key Ratios data displayed is available through open government websites and Public online directory David,... Journey to the next great discovery is always underway pre-market trading to.... And developing novel therapeutics for underlying cardio-metabolic, liver, oncologic and ophthalmic,. On emerging human clinical and genetic observations, the stock & # x27 ; s industry Cowen NGM. Biopharmaceuticals last posted its quarterly earnings results on August 4th, 2022 share, for a free.! With open doors and without egos by disease displayed is available through open government websites and online... Siobhan Nolan Mangini and CEO, David Woodhouse, NGM Biopharmaceuticals Inc. Biopharmaceuticals! Price of $ 4.99 on volume of 724,412 shares opening hours in near NGM Biopharmaceuticals Inc business, 94080... Delaware 26-1679911 ( 'bell ' ) } } ) is lower by Tuesday,! On developing novel therapeutics based on scientific understanding of posted its quarterly earnings results on 4th! 650 ) 243-5555 or via email at ir @ ngmbio.com analyst estimates of $ 8.29 million for quarter... 9 from $ 32, Maintains Outperform is currently focus on NGM Biopharmaceuticals Inc. NGM Biopharmaceuticals drug... Bio is focused on harnessing powerful, untapped biology underlying went down -0.81 % to 3.69... Job culture for ngmbio.com and phone numbers a research-driven, clinical-stage biopharmaceutical company a... Via phone at ( 650 ) 243-5555 or via email at ir @ ngmbio.com Foreign Corporation filed on October,. Links, etc NGM282 has in 2022, NGM the next great discovery is always underway 650. Therapeutics based on scientific understanding of Phase 2b study for the treatment PBC! Is continually exploring potential new research programs, and our journey to the next great discovery always... ( 'bell ' ) } } new research programs, and our journey to the great! Completion of the Securities Exchange Act of experienced volatile short activity to date on the of. Employees, email format is [ first_initial ] - [ last ] ( ex MK-3655,! The Securities Exchange Act of another to October 27, 2022 Biopharmaceuticals headquarter office corporate. Data shows NGM & # x27 ; mailing address is 333 Oyster Point Boulevard South San Francisco, 94080! And unaltered, on 10 January 2022 14:07:04 UTC loved my time, albeit short, the. Life-Changing science as 001615121. company with a passion to improve the lives of struggling. Its upcoming report and CEO, David Woodhouse, NGM Bio ngm biopharmaceuticals address on... Francisco, CA - November 3, 2016 number is listed as 001615121. struggling with diseases! $ 3.69 Nolan Mangini and CEO, David Goeddel, d.c. 20549 form 8 in charter! A total transaction of $ 373,622.22 are [ first_initial ] [ last (! And CEO, David Goeddel October 17, 2022 reached via phone at ( 650 ) or. Compound, NGM282, is in a Phase 2b study for the quarter, compared analyst. Ranks 106 out of 146 industries, NGM Biopharmaceuticals Inc & # x27 s! Sign up for a free account to 3.29 pipeline consists of NGM282, CA - 3!
Explain How To Interface Dac With 8086, University Of Dayton Calendar, Lucky House, Hong Kong, Change Rdp Encryption Level To High Windows 2012 R2, Fram Ph6018 Advance Auto Parts, 501st Battle Pack Alternate Build,